Brief report: Laboratory safety monitoring of chronic medications in ambulatory care settings

AbstractOBJECTIVE: To evaluate laboratory safety monitoring in patients taking selected chronic prescription drugs. DESIGN: Retrospective study using 1999–2001 claims data to calculate rates of missed laboratory tests (potential laboratory monitoring errors). Eleven drugs/drug groups and 64 laboratory tests were evaluated. SETTING: Two staff/network model health maintenance organizations. PATIENTS: Continuously enrolled health plan members age≥19 years taking ≥1 chronic medications. MEASUREMENTS AND MAIN RESULTS: Among patients taking chronic medications (N=29,823 in 1999, N=32,423 in 2000, and N=36,811 in 2001), 47.1% in 1999, 45.0% in 2000, and 44.0% in 2001 did not receive ≥1 test recommended for safety monitoring. Taking into account that patients were sometimes missing more than 1 test for a given drug and that patients were frequently taking multiple drugs, the rate of all potential laboratory monitoring errors was 849/1,000 patients/year in 1999, 810/1,000 patients/year in 2000, and 797/1,000 patients/year in 2001. Rates of potential laboratory monitoring errors varied considerably across individual drugs and laboratory tests. CONCLUSIONS: Lapses in laboratory monitoring of patients taking selected chronic medications were common. Further research is needed to determine whether, and to what extent, this failure to monitor patients is associated with adverse clinical outcomes.

[1]  A. Laupacis,et al.  Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study , 2004 .

[2]  J. McMurray,et al.  Treatment of heart failure with spironolactone--trial and tribulations. , 2004, The New England journal of medicine.

[3]  J. Hernández,et al.  Adverse drug events in ambulatory care. , 2003, The New England journal of medicine.

[4]  T. Welte,et al.  Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases , 2003, BMJ : British Medical Journal.

[5]  Roger B. Davis,et al.  Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. , 2003, Archives of internal medicine.

[6]  D. Bates,et al.  Incidence and preventability of adverse drug events among older persons in the ambulatory setting. , 2003, JAMA.

[7]  D J Graham,et al.  Liver enzyme monitoring in patients treated with troglitazone. , 2001, JAMA.

[8]  G D Schiff,et al.  Prescribing potassium despite hyperkalemia: medication errors uncovered by linking laboratory and pharmacy information systems. , 2000, The American journal of medicine.

[9]  D W Bates,et al.  Incidence and preventability of adverse drug events in nursing homes. , 2000, The American journal of medicine.

[10]  E. Cook,et al.  Drug complications in outpatients , 2000, Journal of general internal medicine.

[11]  P. Corey,et al.  Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[12]  G P Samsa,et al.  Adverse Drug Events In High Risk Older Outpatients , 1997, Journal of the American Geriatrics Society.

[13]  E. Wyllie,et al.  Routine laboratory monitoring for serious adverse effects of antiepileptic medications: the controversy. , 1991, Epilepsia.